In addition, we found that ATIII treatment reduced induction of the transcription factor MYC, expression of which has been associated with progression of liver disease to chronic hepatitis, cirrhosis, and hepatocellular carcinoma[52,59]. This evidence concerns the gene SERPINC1 and chronic hepatitis.